NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT01471106 2024-07-10
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT06355037 2024-07-08
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Fudan University
Phase 2 Recruiting
NCT02720185 2022-06-03
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
University of Wisconsin, Madison
Phase 2 Terminated
NCT00780676 2020-09-03
Personalized Treatment Selection for Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00410813 2017-07-02
S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone
SWOG Cancer Research Network
Phase 2 Completed
NCT00696072 2016-06-13
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Bristol-Myers Squibb
Phase 2 Completed
NCT00754325 2016-05-26
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
Bristol-Myers Squibb
Phase 2 Completed
NCT01410708 2016-02-17
TORI 104 Pre-Surgical Dasatinib
AHS Cancer Control Alberta
Phase 2 Withdrawn
NCT00546104 2013-07-17
Phase II Dasatinib Study in Advanced Breast Cancer
Duke University
Phase 2 Completed
NCT00767520 2013-02-28
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00817531 2012-08-31
Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients
Baylor Breast Care Center
Phase 2 Terminated
NCT00371345 2011-04-26
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00371254 2011-03-15
A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed